Medications for Coronary Artery Disease (CAD)
The optimal pharmacological treatment for coronary artery disease requires a combination of antiplatelet therapy, statins, beta-blockers, and ACE inhibitors to reduce mortality and morbidity, with additional symptom-relieving medications as needed. 1
Core Medications for CAD
Antiplatelet Therapy
For all patients with established CAD:
For patients after Acute Coronary Syndrome (ACS) or PCI:
- Dual antiplatelet therapy (DAPT) is recommended:
- After DAPT period, continue single antiplatelet therapy indefinitely 1
Lipid-Lowering Therapy
- Statins:
- Recommended for all patients with CAD 1
- High-intensity statins (e.g., atorvastatin 40-80 mg) preferred for maximum LDL-C reduction 2
- If target LDL-C not achieved with maximum tolerated statin dose, add ezetimibe 1
- For very high-risk patients not reaching goals with statin plus ezetimibe, add PCSK9 inhibitor 1
Beta-Blockers
- Strongly recommended as initial therapy for chronic stable angina 1
- Essential component of treatment for reducing morbidity and mortality, especially in patients with prior MI 1
- Particularly beneficial in patients with hypertension and post-MI 1
- Not contraindicated in diabetes; diabetic patients may benefit more than non-diabetics 1
ACE Inhibitors/ARBs
- Recommended for all CAD patients, especially those with:
- Heart failure
- Hypertension
- Diabetes
- Previous MI 1
- Reduce cardiovascular death, MI, and stroke even in patients without heart failure 1
- ARBs recommended as alternative for patients who cannot tolerate ACE inhibitors 1
Symptom Relief Medications
Nitrates
- Sublingual nitroglycerin for immediate relief of angina 1
- Long-acting nitrates for symptom control, though they have not been shown to reduce mortality 1
Calcium Channel Blockers (CCBs)
- Long-acting or slow-release dihydropyridines (e.g., amlodipine) or non-dihydropyridines (e.g., diltiazem, verapamil) for symptom relief 1
- Avoid immediate-release or short-acting dihydropyridine CCBs as they may increase adverse cardiac events 1
- Use with caution in patients with heart failure with reduced ejection fraction 1
Additional Anti-Anginal Agents
- Ranolazine: Consider as add-on therapy when symptoms persist despite beta-blockers and/or CCBs 3
Special Considerations
Diabetic Patients with CAD
- SGLT2 inhibitors (empagliflozin, canagliflozin, dapagliflozin) recommended to reduce CV events 1
- GLP-1 receptor agonists (liraglutide, semaglutide, dulaglutide) recommended to reduce CV events 1
- ACE inhibitors particularly beneficial for secondary prevention 1
Patients with Heart Failure and CAD
- Beta-blockers, ACE inhibitors/ARBs, and mineralocorticoid receptor antagonists (MRAs) are essential 1
- Avoid thiazolidinediones in patients with heart failure 1
- Consider sacubitril/valsartan instead of ACE inhibitors in patients with HFrEF who remain symptomatic 1
Common Pitfalls and Caveats
Underuse of aspirin: Despite strong evidence supporting its use, aspirin is often underutilized in CAD patients 4. Ensure all eligible patients receive appropriate antiplatelet therapy.
Inadequate statin dosing: Many patients don't receive high-intensity statins or fail to reach LDL-C goals. Optimize statin therapy and consider combination therapy when needed 1.
Medication interactions: Be cautious with drug combinations that may increase bleeding risk (e.g., triple therapy with dual antiplatelet plus anticoagulant) or prolong QT interval (e.g., ranolazine with other QT-prolonging medications) 3.
Gastrointestinal bleeding risk: Consider proton pump inhibitors in patients on antiplatelet therapy who are at high risk for GI bleeding 1.
Diabetes management: In diabetic patients with CAD, prioritize medications with proven cardiovascular benefits (SGLT2 inhibitors, GLP-1 RAs) 1.
By implementing this comprehensive medication regimen tailored to individual patient characteristics, CAD management can significantly reduce mortality, prevent cardiovascular events, and improve quality of life.